Eravacycline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Eravacycline: From Complicated Intra-abdominal Infections to Bronchitis
One-Sentence Summary
Eravacycline is a fourth-generation tetracycline (fluorocycline) antibiotic, currently indicated for complicated intra-abdominal infections. The TxGNN model predicts it may be effective for Bronchitis, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph association with no direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Complicated intra-abdominal infections (cIAI) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 96.85% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, eravacycline is a broad-spectrum fluorocycline antibiotic active against many Gram-positive, Gram-negative, and anaerobic organisms, with proven efficacy in complicated intra-abdominal infections.
Mechanistically, if the underlying pathology of bronchitis is bacterial, it could theoretically fall within eravacycline’s antimicrobial spectrum. However, its approved indication and available data are limited to intra-abdominal infection, and there is no pharmacokinetic data (e.g., lung tissue penetration) or clinical experience supporting its use in respiratory tract infections. The high TxGNN score appears to reflect a graph-level association rather than a validated pharmacological rationale.
Eravacycline is also only available as an intravenous formulation, which further limits its practical suitability for an outpatient condition such as bronchitis, where oral antibiotics are the standard of care.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported only by a TxGNN model score (L5), with no clinical trials, published literature, or mechanistic/pharmacokinetic data linking eravacycline to bronchitis. The IV-only formulation further limits clinical feasibility for this indication.
To proceed, the following is needed:
- Confirmed mechanism of action data (currently a data gap)
- TFDA/EMA label warnings and contraindications (currently a data gap, blocking safety review)
- Pharmacokinetic data on lung tissue penetration
- Preclinical or clinical evidence specific to respiratory tract infections
- Reassessment of route compatibility (IV-only vs. outpatient bronchitis treatment norms)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.